169 related articles for article (PubMed ID: 19098003)
21. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
[TBL] [Abstract][Full Text] [Related]
22. Periodic Mechanical Stress Activates PKCδ-Dependent EGFR Mitogenic Signals in Rat Chondrocytes via PI3K-Akt and ERK1/2.
He P; Shen N; Gao G; Jiang X; Sun H; Zhou D; Xu N; Nong L; Ren K
Cell Physiol Biochem; 2016; 39(4):1281-94. PubMed ID: 27606614
[TBL] [Abstract][Full Text] [Related]
23. Betacellulin and amphiregulin induce upregulation of cyclin D1 and DNA synthesis activity through differential signaling pathways in vascular smooth muscle cells.
Shin HS; Lee HJ; Nishida M; Lee MS; Tamura R; Yamashita S; Matsuzawa Y; Lee IK; Koh GY
Circ Res; 2003 Aug; 93(4):302-10. PubMed ID: 12869389
[TBL] [Abstract][Full Text] [Related]
24. Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors.
Rohrbach S; Yan X; Weinberg EO; Hasan F; Bartunek J; Marchionni MA; Lorell BH
Circulation; 1999 Jul; 100(4):407-12. PubMed ID: 10421602
[TBL] [Abstract][Full Text] [Related]
25. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.
Gilbertson RJ; Bentley L; Hernan R; Junttila TT; Frank AJ; Haapasalo H; Connelly M; Wetmore C; Curran T; Elenius K; Ellison DW
Clin Cancer Res; 2002 Oct; 8(10):3054-64. PubMed ID: 12374672
[TBL] [Abstract][Full Text] [Related]
26. An anti-oncogenic role for decorin. Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells.
Santra M; Eichstetter I; Iozzo RV
J Biol Chem; 2000 Nov; 275(45):35153-61. PubMed ID: 10942781
[TBL] [Abstract][Full Text] [Related]
27. Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype.
Telesco SE; Vadigepalli R; Radhakrishnan R
Biotechnol J; 2013 Dec; 8(12):1452-64. PubMed ID: 24318637
[TBL] [Abstract][Full Text] [Related]
28. Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene.
Buxbaum JD; Georgieva L; Young JJ; Plescia C; Kajiwara Y; Jiang Y; Moskvina V; Norton N; Peirce T; Williams H; Craddock NJ; Carroll L; Corfas G; Davis KL; Owen MJ; Harroch S; Sakurai T; O'Donovan MC
Mol Psychiatry; 2008 Feb; 13(2):162-72. PubMed ID: 17579610
[TBL] [Abstract][Full Text] [Related]
29. JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5.
Cleyrat C; Jelinek J; Girodon F; Boissinot M; Ponge T; Harousseau JL; Issa JP; Hermouet S
Leukemia; 2010 May; 24(5):1069-73. PubMed ID: 20182460
[No Abstract] [Full Text] [Related]
30. Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.
Stoll SW; Kansra S; Peshick S; Fry DW; Leopold WR; Wiesen JF; Sibilia M; Zhang T; Werb Z; Derynck R; Wagner EF; Elder JT
Neoplasia; 2001; 3(4):339-50. PubMed ID: 11571634
[TBL] [Abstract][Full Text] [Related]
31. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
Pan Y; Xu Y; Feng S; Luo S; Zheng R; Yang J; Wang L; Zhong L; Yang HY; Wang BL; Yu Y; Liu J; Cao Z; Wang X; Ji P; Wang Z; Chen X; Zhang S; Wei YQ; Yang SY
Mol Cancer Ther; 2012 Apr; 11(4):952-62. PubMed ID: 22319204
[TBL] [Abstract][Full Text] [Related]
32. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines.
Williams EE; Trout LJ; Gallo RM; Pitfield SE; Bryant I; Penington DJ; Riese DJ
Cancer Lett; 2003 Mar; 192(1):67-74. PubMed ID: 12637154
[TBL] [Abstract][Full Text] [Related]
33. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
Das R; Mahabeleshwar GH; Kundu GC
J Biol Chem; 2004 Mar; 279(12):11051-64. PubMed ID: 14704150
[TBL] [Abstract][Full Text] [Related]
34. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
Li Z; Mei Y; Liu X; Zhou M
Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
[TBL] [Abstract][Full Text] [Related]
35. Dexamethasone modulates ErbB tyrosine kinase expression and signaling through multiple and redundant mechanisms in cultured rat hepatocytes.
Scheving LA; Buchanan R; Krause MA; Zhang X; Stevenson MC; Russell WE
Am J Physiol Gastrointest Liver Physiol; 2007 Sep; 293(3):G552-9. PubMed ID: 17585012
[TBL] [Abstract][Full Text] [Related]
36. An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival.
Zhang K; Wong P; Duan J; Jacobs B; Borden EC; Bedogni B
Pigment Cell Melanoma Res; 2013 May; 26(3):408-14. PubMed ID: 23480537
[TBL] [Abstract][Full Text] [Related]
37. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
38. Neuregulin signaling in the heart. Dynamic targeting of erbB4 to caveolar microdomains in cardiac myocytes.
Zhao YY; Feron O; Dessy C; Han X; Marchionni MA; Kelly RA
Circ Res; 1999 Jun; 84(12):1380-7. PubMed ID: 10381889
[TBL] [Abstract][Full Text] [Related]
39. Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y(1086), c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity.
Cardoso AP; Pinto ML; Pinto AT; Oliveira MI; Pinto MT; Gonçalves R; Relvas JB; Figueiredo C; Seruca R; Mantovani A; Mareel M; Barbosa MA; Oliveira MJ
Oncogene; 2014 Apr; 33(16):2123-33. PubMed ID: 23644655
[TBL] [Abstract][Full Text] [Related]
40. Desensitization by different strategies of epidermal growth factor receptor and ErbB4.
Yamamoto H; Higa-Nakamine S; Noguchi N; Maeda N; Kondo Y; Toku S; Kukita I; Sugahara K
J Pharmacol Sci; 2014; 124(3):287-93. PubMed ID: 24553453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
